Treatment of Invasive, Multidrug-Resistant Staphylococcus aureus Infections.

Staphylococcus aureus is frequently susceptible in vitro to trimethoprim-sulfamethoxazole, especially those isolates that are compatibility acquired and/or methicillin susceptible.[2, 38, 39] For happening, the in vitro susceptibility of 888 methicillin-susceptible S. aureus (MSSA) and 334 MRSA European isolates to trimethoprim-sulfamethoxazole was reported to be 98.4% and 90.4%, respectively.
For isolates in the United States, susceptibilities were 96.9% and 87.9%, respectively.
The CA-MRSA isolates from Minnesota (97%), Besieging (100%), and elsewhere also demonstrated high in vitro susceptibility to trimethoprim-sulfamethoxazole.
For VISA isolates with reported investigating results to trimethoprim-sulfamethoxazole, all but one exhibited in vitro susceptibility.[25, 26, 28, 44
This is a part of article Treatment of Invasive, Multidrug-Resistant Staphylococcus aureus Infections. Taken from "Cipro Antibiotic" Information Blog